New research suggests that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle programs.
Research printed in a prominent health publication points out that while obese individuals can lose a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such drugs must be cognizant of the risk of quick weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to original weight within about 18 months.
Analyzing Treatments
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.
Scientists emphasize that individuals who shed pounds through dieting generally see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Experts suggest the mode of action of the injections is key to understanding the amplified regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the therapy might need to be life-long.
This perspective is supported by drug manufacturers, who note that the results "underscore the persistent character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
People who have stopped the medication report a sudden return of hunger.
"It felt as if something that goes on and you become ravenous," said a patient.
This challenge is exacerbated if users have not established lasting lifestyle or habit modifications during treatment.
Significant Use
Survey data show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Finally, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on integrated behavioural changes.
